Newsfile Corp
16 Aug 2026, 21:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Capricor's lead product candidate, Deramiocel. — Negative advisory committee votes for a lead product candidate significantly increase the probability of FDA rejection, destroying the primary value driver for a biotech company.
-0.90The FDA alleged that Capricor used a statistical analysis plan (SAP) for clinical data that was not agreed upon prior to BLA submission and was considered post-hoc and exploratory. — Allegations of data manipulation or improper statistical methodology undermine the scientific integrity of trial results and risk regulatory failure.
-0.70A class action lawsuit has been filed against Capricor Therapeutics and its executives for alleged violations of the Securities Exchange Act of 1934. — Securities litigation creates legal liabilities and overhangs, though it is often a trailing result of the stock price drops already experienced.
-0.40Continue reading
6 related stories
Search tags
Capricor stock experienced two major crashes, falling 64% and 36% following the release of FDA briefing documents and the advisory committee vote. — While this is historical price action, it confirms the market's severe devaluation of the company's current pipeline prospects.
-0.20Which stocks this story touches
The company is facing a class action lawsuit alleging securities fraud, regulatory setbacks for its lead product, and a massive collapse in stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
50m ago
